UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 121

of 'Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia'

121
TI
Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
AU
Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ
SO
J Perinatol. 2007;27(4):241.
 
Treatment of maternal chronic myeloid leukemia with imatinib mesylate is avoided because of potential fetal effects. Two women with progression of disease during pregnancy required imatinib therapy. Concentrations of imatinib in maternal blood, placenta, umbilical cord blood and breast milk were 886, 2452, 0 to 157, and 596 ng/ml, respectively. Concentrations of the active metabolite CGP74588 in maternal blood, placenta, umbilical cord blood and breast milk were 338, 1462, 0 and 1513 ng/ml, respectively. As Imatinib and CGP74588 cross the mature placenta poorly, use of the drug after the first trimester may be reasonable under some circumstances. Imatinib and CGP74588 are found in breast milk, and therefore avoidance of breastfeeding is advisable.
AD
VA Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, VT 05009, USA. Michelle.A.Russell@dartmouth.edu
PMID